Genomic Valley Biotech Ltd - 539206 - Submission Of Compliance Certificate Pursuant To Regulation 7 (3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Please find enclosed herewith the Compliance Certificate pursuant to Regulation 7 (3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the half year ended on 31st March, 2021. Genomic Valley Biotech Ltd - 539206 - Intimation Regarding The Applicability Of SEBI Circular No. SEBI/HO/DDHS/CIR/P/2018/144
This is to confirm you that Genomic Valley Biotech Limited ('Company') do not fall under the ambit of 'Large Entities' as per the SEBI Circular No. SEBI/HO/DDHS/CIR/P/2018/144 regarding the Fund raising of Debt Securities by Large Entities and do not have an outstanding long term borrowing of Rs. 100 crores or above with original maturity of more than one (1) year. Genomic Valley Biotech Ltd - 539206 - Disclosure Under Regulation 30(1), 30(2) & 31(4) Of SEBI (Substantial Acquisition Of Shares And Takeovers) Regulations, 2011
This is in reference to the requirements of disclosures under Regulation 30(1), 30(2) & 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as per the requirement, we have received the disclosures under aforesaid regulation from all the promoters with respect to their shareholding as on 31st March 2021. We are enclosing herewith for your reference. Genomic Valley Biotech Ltd - 539206 - Appointment of Company Secretary and Compliance Officer
Pursuant to the Regulation 30 and other applicable Regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby intimate that the Board of Directors of the Company has approved the following appointment in the Board Meeting held on today i.e. 06.04.2021: 1. Appointment of Mrs. Monisha Meghna (Membership No. A41747) as Company Secretary and Compliance Officer of the Company with effect from 06.04.2021. Genomic Valley Biotech Ltd - 539206 - Closure of Trading Window
Pursuant to the Code of Conduct for Prevention of Insider Trading of the Company under SEBI(Prohibition of Insider Trading) Regulations, 2015, as amended from time to time, we would like to inform you that the trading window for the purpose of trading in the securities of the Company by its Designated persons shall remain closed from April 01, 2021 till 48 (Forty Eight) hours after the conclusion of the Meeting of the Board of Directors of the Company to be held to consider and approve the Audited Financial Results of the Company for the quarter and year ended March 31, 2021. The date and venue of Board Meeting for the aforesaid purpose shall be intimated to you in due course. Please take the above on records and acknowledge the receipt of the same. Genomic Valley Biotech Ltd - 539206 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Advertisements published for the Un-Audited Financial Results for the quarter and nine months ended December 31, 2020 in the newspapers, Financial Express (English Edition) and Jansatta (Hindi Edition) on 12th February, 2021. Genomic Valley Biotech Ltd - 539206 - Intimation Of Appointment Of Rohit Batham & Associates, Practicing Company Secretaries And Andros & Co., Chartered Accountants
1. Pursuant to the Regulation 24A of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirement) Regulations, 2015 read with Circular No. CIR/CFD/CMD1/27/2019 dated February 08, 2019 issued by Securities and Exchange Board of India and other applicable provisions thereto, if any, the Board of Directors, in its meeting held today, has approved the appointment of Rohit Batham & Associates, Practicing Company Secretaries, with immediate effect to issue Annual Secretarial Compliance Report for the Financial Year 2020-21. 2. Pursuant to the Regulation 76 of SEBI (Depositories and Participants) Regulations, 1996 and any other provision applicable thereto, if any, the Board of Directors, in its meeting held today, has approved the appointment of Andros & Co., Chartered Accountants, with immediate effect to issue Reconciliation of Share Capital Audit Report on quarterly basis for the Financial Year 2021-22. Genomic Valley Biotech Ltd - 539206 - Un-Audited Financial Results For The Quarter And Nine Months Ended 31St December, 2020
Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Board of Directors of Genomic Valley Biotech Limited ('Company') in its meeting held today approved the Un-Audited Financial Results (Standalone) for the Quarter and Nine Months ended 31st December, 2020 of the Company as per Indian Accounting Standards (IND-AS) along with the Limited Review Report. Copy of the results along with the Limited Review Report of Statutory Auditors is attached herewith for your perusal. Genomic Valley Biotech Ltd - 539206 - Submission Of Outcomes Of Board Meeting And Un-Audited Financial Results For The Quarter And Nine Months Ended 31St December, 2020
Intimation and disclosure under Regulations 30 & 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for Un-Audited Financial Results and Limited Review Report for the quarter and nine months ended 31.12.2020 and other disclosures Genomic Valley Biotech Ltd - 539206 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Please find enclosed herewith the Newspaper Advertisements published for the Notice of Board Meeting to be held on 11th February, 2021, inter-alia, to consider and approve the Un-Audited Financial Results for the quarter and nine months ended 31st December, 2020, in the newspapers, Financial Express (English Edition) and Jansatta (Hindi Edition) on 03rd February, 2021.